You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)子公司獲非獨家許可生產新冠藥物
復星醫藥(02196.HK)(600196.SH)公布,藥品專利池組織(MPP)授予公司子公司復星醫藥產業使用相關專利和專有技術,對「奈瑪特韋(Nirmatrelvir)」的仿製藥和許可產品「奈瑪特韋/利托那韋組合」開展生產,並在區域內(即印度、巴基斯坦、科特迪瓦等95個中低收入國家,不包括中國)對許可產品進行商業化(包括註冊、零售、分銷等)及相關權利的非獨家許可。 許可產品是一個組合包裝的口服小分子新冠治療藥物,其包括兩個抗病毒藥物,即奈瑪特韋(Nirmatrelvir)和利托那韋(Ritonavir)。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account